People with diabetes are benefiting from advances successful medications and technologies to little their hazard of hypoglycemia, according to a Clinical Practice Guideline issued contiguous by the Endocrine Society.
The guideline, titled "Management of Individuals with Diabetes astatine High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline," was published online and volition look successful the March 2023 people contented of The Journal of Clinical Endocrinology & Metabolism (JCEM), a work of the Endocrine Society.
Hypoglycemia is the word for episodes of dangerously debased humor sweetener successful radical with diabetes. Patients with terrible hypoglycemia whitethorn acquisition unconsciousness oregon seizures, and the information tin importantly impact a person's prime of life, societal life, enactment productivity and quality to thrust safely. It is communal successful radical with benignant 1 diabetes, and successful those with 2 diabetes who are taking insulin oregon sulfonylureas, and galore radical bash not acquisition oregon admit the symptoms.
Hypoglycemia is identified arsenic 1 of the apical 3 preventable adverse cause reactions by the US Department of Health and Human Services. Between January 2007 and December 2011, exigency section visits for therapy-associated hypoglycemia among Medicare beneficiaries resulted successful much than $600 cardinal successful spending.
This line updates the Society's 2009 inpatient hypoglycemia line and focuses solely connected radical with diabetes-related hypoglycemia. It incorporates recommendations to dainty and negociate hypoglycemia much efficaciously utilizing caller insulins and forms of glucagon, and advancements successful continuous glucose monitoring (CGM) and insulin pump technology.
"CGMs and insulin pumps person been overmuch much commonly utilized successful the past decennary among radical with diabetes including children, and determination are caller forms of glucagon available. We had to update our line to lucifer these developments successful the diabetes field," said Anthony L. McCall, M.D., Ph.D., of the University of Virginia successful Charlottesville, Va. McCall is the seat of the sheet that wrote the guideline. "People with diabetes, their caregivers and diabetes specialists volition each payment from our line with a amended knowing of champion practices and interventions."
Key recommendations from the line include:
- Prescribing easier-to-use formulations of glucagon for radical with terrible hypoglycemia;
- Leveraging CGM alternatively than self-monitoring of humor glucose by fingerstick for patients with benignant 1 diabetes receiving aggregate regular injections;
- Conducting inpatient glycemic surveillance and absorption programs leveraging physics wellness grounds (EHR) information for inpatients astatine hazard for hypoglycemia; and
- Utilizing structured diligent acquisition programs for big and pediatric patients with benignant 1 diabetes oregon benignant 2 diabetes receiving insulin therapy.
Additional line resources see the Endocrine News Q&A with the co-chairs and the Society's hypoglycemia diligent resources.
Other members of the Endocrine Society penning committee that developed this line include: David C. Lieb (co-chair) of Eastern Virginia Medical School successful Norfolk, Va.; Roma Gianchandani of Cedars Sinai successful Los Angeles, Calif.; Heidemarie MacMaster of Lahey Health successful Burlington, Mass.; Gregory A. Maynard of the University of California Davis successful Davis, Calif.; M. Hassan Murad of Mayo Clinic successful Rochester, Minn.; Elizabeth Seaquist of the University of Minnesota successful Minneapolis, Minn.; Joseph I. Wolfsdorf of Boston Children's Hospital successful Boston, Mass.; Robin Fein Wright of DiabetesSisters successful Bolingbrook, Ill.; and Wojtek Wiercioch of McMaster University successful Hamilton, Ontario.
Victor Torres Roldan of the Mayo Evidence-Based Practice Center conducted the grounds reviews for the guideline, and Drs. Jane Seley and Grazia Aleppo made important technological contributions. Maureen Corrigan, Director for Clinical Practice Guidelines for the Endocrine Society assisted with each aspects of line development.
The Society established its Clinical Practice Guideline Program to supply endocrinologists and different clinicians with evidence-based recommendations successful the diagnosis, treatment, and absorption of endocrine-related conditions. Each line is developed by a multidisciplinary sheet of topic-related experts successful the field. Guideline improvement panels trust connected evidence-based reviews of the lit successful the improvement of line recommendations. The Endocrine Society does not solicit oregon judge firm enactment for its guidelines. All Clinical Practice Guidelines are supported wholly by Society funds.
This Clinical Practice Guideline was co-sponsored by the American Association of Clinical Endocrinology, the American Diabetes Association, DiabetesSisters, the Pediatric Endocrine Society and the Society for Hospital Medicine.
English (US)